SUPPLEMENTARY MATERIAL

Design potential selective inhibitors for human leukocyte common antigen-related (PTP-LAR) with fragment replace approach

Jing-Wei Wua,1, Huan Zhang b,1, Wei-Ya Lia,1,Xue Tangc, Hong-Lian Lia, Xin-Hua Lud, Zhi-Hui Zhengd, Ying Maa,\*, Run-Ling Wanga,\*

aTianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin 300070, China; Tel/Fax: +86-22-83336690;

bDepartment of Pharmacy, Tianjin Medical University General Hospital, Tianjin 300052, China; Tel/Fax: +86-22-60362235;

cTasly Research Institute, Tasly Holding Group Co., Ltd, Tianjin

dNew Drug Research and Development Center of North China Pharmaceutical Group Corporation, National Microbial Medicine Engineering and Research Center, Hebei Industry Microbial Metabolic Engineering &Technology Research Center, Key Laboratory for New Drug Screening Technology of Shijiazhuang City, Shijiazhuang, Hebei, China.

1 These authors contributed equally to this work;

 \*Corresponding author. Email-address: maying@tmu.edu.cn (Y Ma); wangrunling@tmu.edu.cn (R.-L. Wang).



Figure S1 Relationship between the experimental pIC50 and the docking score of 20 inhibitors of LAR (R2=0.93).



Figure S2 The 2D diagram of LAR-compound 7f.



Figure S3 The docked poses of 20 inhibitors of PTP-LAR